4:10 PM ET
8-K
Clinical Trial Data
SpyGlass Pharma Clinical Trial Data
SpyGlass Pharma announced positive 4-year interim results from its first-in-human trial of the BIM-IOL System for glaucoma patients undergoing cataract surgery. The data showed a 37% reduction in mean intraocular pressure and 86% of patients remained off topical drops with no product-related adverse events reported.
- Term
- 4 years